How did CRVO's Q1 2024 EPS surprise impact investor confidence?

CervoMed (CRVO) experienced a negative EPS surprise of -0.2 in Q1 2024, which represents a decrease of 1.42% from the previous quarter. This negative surprise likely had a bearish impact on investor confidence, as it indicates the company's performance fell short of analysts' expectations. Investors may interpret this as a sign of potential issues within the company, leading to a decrease in confidence in its future performance.